Logo

NEWSBRIEF: Myriad Genetics Sees Revenue Rise, Widened Losses in Q3

May 07, 2002

SAN FRANCISCO, May 7 - Myriad Genetics today reported increased revenue and widened losses for the third quarter of fiscal 2002.

 

Total revenue for the third quarter ended March 31 was $13.1 million compared with $11.6 million in the year-ago period.

 

The net loss for the quarter was $3.5 million, or $.15 per share, compared to $1.7 million, or $.07 a share, for the same period a year ago.


R&D spending for the quarter rose to approximately $8.7 million from $8.4 million for the year-ago period. 

 

The company said it had $125.7 million in cash and investments as of March 31.

 

Click here for more information.

Breaking News
The Scan

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.

Algorithm Teases Out Genetic Ancestry in Individuals at Biobank Scale

Researchers develop an algorithm known as Rye to tease apart ancestry fractions in admixed individuals at a biobank-scale, applying it to 488,221 UK Biobank participants in Nucleic Acids Research.

Multi-Ancestry Analysis Highlights Comparable Common Variants at Complex Trait-Linked Loci

Researchers in Nature Genetics examine common variants implicated in more than three dozen conditions, estimating genetic effect similarities across ancestry tracts in admixed individuals.

Sick Newborns Selected for WGS With Automated Pipeline

Researchers successfully prioritized infants with potential Mendelian conditions for whole-genome sequencing or rapid whole-genome sequencing, as they report in Genome Medicine.